The Outpatient Prospective Payment System (OPPS) proposed rule has come out! It will take time to read and digest so details will follow. At first glance, there are no changes to Cellular Tissue Product /skin substitute payment, which remain under package pricing in this site of care. Of note, “skin substitutes” are considered medical supplies for payment purposes. Stay tuned for more information as the proposed rule is evaluated.
Here is a link to the CMS fact sheet.
Submit the form below to receive email alerts when Intellicure publishes a new blog post! This information will not be shared.
You May Also Like …
I may post more information about the meeting later, but the general tone of the MAC medical directors was confident.
CGS J15 Webinar on Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
The American Medical Association (AMA) and the Illinois State Medical Society (ISMS) have filed a lawsuit in federal court.